the patients , whose asthma was considered not adequately controlled , were divided into two groups according to their principal medication at entry ( group a , oral and/or inhaled beta 2-bronchodilators ; group b , methylxanthines , with or without beta 2-agonists ) and randomly allocated to additional treatment with cromolyn sodium ( metered-dose inhaler , 2 mg , four times a day , or capsules , 20 mg , four times a day ) or matching placebo .
C0004096
asthma
C0012694
cromolyn